For the year ending 2025-12-31, EDIT had $13,897K increase in cash & cash equivalents over the period. -$165,848K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -160,060 |
| Stock-based compensation expense | 10,000 |
| Depreciation | 5,277 |
| Loss on disposal of fixed assets | -2,193 |
| Net accretion of discounts on marketable securities | 902 |
| Interest related to sale of future revenues | 6,171 |
| Impairment of held for sale assets | 3,758 |
| Other non-cash items, net | 449 |
| Accounts receivable | -1,090 |
| Prepaid expenses and other current assets | -1,062 |
| Right-of-use assets | -11,584 |
| Other non-current assets | -1,040 |
| Accounts payable | -2,888 |
| Accrued expenses | -13,184 |
| Accrued interest on sale of future revenues | -2,128 |
| Deferred revenue | -15,916 |
| Operating lease liabilities | -12,081 |
| Other non-current liabilities | 192 |
| Net cash used in operating activities | -165,241 |
| Purchases of property and equipment | 607 |
| Proceeds from the sale of equipment | 269 |
| Purchases of marketable securities | 0 |
| Proceeds from maturities of marketable securities | 139,006 |
| Net cash provided by investing activities | 138,668 |
| Repayment on sale of future revenues | 2,872 |
| Proceeds from offering of common stock, net of issuance costs | 42,848 |
| Proceeds from sale of future revenues, net | 0 |
| Proceeds from exercise of stock options | 70 |
| Issuance of common stock under benefit plans | 424 |
| Net cash provided by financing activities | 40,470 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 13,897 |
| Cash, cash equivalents, and restricted cash, beginning of period | 135,418 |
| Cash, cash equivalents, and restricted cash, end of period | 149,315 |
Editas Medicine, Inc. (EDIT)
Editas Medicine, Inc. (EDIT)